Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 23;9:1041044. doi: 10.3389/fcvm.2022.1041044

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Yu, Yang, Tong, Yin, Hu, Zhang, Jiang, Zhou and Jian.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Meta-analysis and TSA results of glycemic-related indicators in dorzagliatin vs. placebo in the treatment of T2DM. (A) Meta-analysis and TSA results of HbAlc in dorzagliatin vs. placebo in the treatment of T2DM. (B) Meta-analysis and TSA results of FPG in dorzagliatin vs. placebo in the treatment of T2DM. (C) Meta-analysis and TSA results of 2h-PPG in dorzagliatin vs. placebo in the treatment of T2DM. (D) Meta-analysis and TSA results of HOMA2-β in dorzagliatin vs. placebo in the treatment of T2DM. (E) Meta-analysis and TSA results of HOMA2-IR in dorzagliatin vs. placebo in the treatment of T2DM.